Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Fungal Infection Reports
Published in: Current Fungal Infection Reports 2/2011

01-06-2011

Antifungal Dosing in Dialysis and Continuous Renal Replacement Therapy

Author: Douglas N. Fish

Published in: Current Fungal Infection Reports | Issue 2/2011

Login to get access

Abstract

Appropriate dosing of antifungal drugs is crucial to achieving favorable outcomes in patients with invasive fungal infections. The use of various types of renal replacement therapy (RRT) in patients with severe acute or chronic renal insufficiency adds another level of complexity to the already challenging use of these drugs. The medical literature provides only a limited number of studies specifically addressing the use of antifungal agents in patients receiving RRT, and there are a number of inherent difficulties in interpreting and applying these studies of drug dosing during RRT to individual patients. This article briefly reviews recent studies examining the dosing of antifungal agents during RRT, and also briefly reviews device-related and drug-related factors that determine the removal of drugs during RRT. Finally, this article summarizes current recommendations for dosing of antifungal agents in patients receiving RRT and highlights areas for future study.
Literature
1.
Uchino S, Kellum JA, Bellomo R, et al. Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA. 2005;294:813–8.PubMedCrossRef
2.
Ricci Z, Ronco C, D’Amico G, et al. Practice patterns in the management of acute renal failure in the critically ill patient: an international survey. Nephrol Dial Transplant. 2006;21:690–6.PubMedCrossRef
3.
Uchino S, Bellomo R, Morimatsu H, et al. Continuous renal replacement therapy: a worldwide practice survey. The beginning and ending supportive therapy for the kidney (B.E.S.T. kidney) investigators. Intensive Care Med. 2007;33:1563–70.PubMedCrossRef
4.
Schetz M. Drug dosing in continuous renal replacement therapy: general rules. Curr Opin Crit Care. 2007;13:645–51.PubMedCrossRef
5.
Bouman CSC. Antimicrobial dosing strategies in critically ill patients with acute kidney injury and high-dose continuous veno-venous hemofiltration. Curr Opin Crit Care. 2008;14:654–9.PubMedCrossRef
6.
Choi G, Gomersall CD, Tian Q, et al. Principles of antibacterial dosing in continuous renal replacement therapy. Crit Care Med. 2009;37:2268–82.PubMedCrossRef
7.
•• Heintz BH, Matzke GR, Dager WE. Antimicrobial dosing concepts and recommendations for critically ill patients receiving continuous renal replacement therapy or intermittent hemodialysis. Pharmacother. 2009;29:562–77. This review provides an overview of RRT techniques, factors that influence drug removal, and dosing during RRT, and also provides recommendations for dosing of both antibacterial and antifungal drugs. It is currently the most comprehensive review article of its type. CrossRef
8.
Wagner C, Graninger W, Presterl E, et al. The echinocandins: comparison of their pharmacokinetics, pharmacodynamics and clinical applications. Pharmacol. 2006;78:161–77.CrossRef
9.
• Lipp H-P. Antifungal agents – clinical pharmacokinetics and drug interactions. Mycoses. 2008;51 Suppl 1:7–18. This review article provides a brief overview of the pharmacokinetics of the various antifungal agents and provides a good foundation for evaluation of the use of these drugs during RRT. PubMedCrossRef
10.
Sucher AJ, Chahine EB, Balcer HE. Echinocandins: the newest class of antifungals. Ann Pharmacother. 2009;43:1647–57.PubMedCrossRef
11.
Mazzei T, Novelli A. Pharmacological properties of antifungal drugs with a focus on anidulafungin. Drugs. 2009;69 Suppl 1:79–90.PubMedCrossRef
12.
Li Y, Theuretzbacher U, Clancy CJ, et al. Pharmacokinetic/pharmacodynamic profile of posaconazole. Clin Pharmacokinet. 2010;49:379–96.PubMedCrossRef
13.
Anonymous: Antifungal drug monographs. In 2011 AHFS Drug Information. Bethesda, MD: American Society of Health-System Pharmacists; 2011.
14.
Valtonen M, Tiula E, Neuvonen PJ. Effect of continuous venovenous haemofiltration and haemodiafiltration on the elimination of fluconazole in patients with acute renal failure. J Antimicrob Chemother. 1997;40:695–700.PubMedCrossRef
15.
Pittrow L, Penk A. Dosage adjustment of fluconazole during continuous renal replacement therapy (CAVH, CVVH, CAVHD, CVVHD). Mycoses. 1999;42:17–9.PubMedCrossRef
16.
Muhl E, Martens T, Iven H, et al. Influence of continuous veno-venous haemodiafiltration and continuous veno-venous haemofiltration on the pharmacokinetics of fluconazole. Eur J Clin Pharmacol. 2000;56:671–8.PubMedCrossRef
17.
Yagasaki K, Gando S, Matsuda N, et al. Pharmacokinetics and the most suitable dosing regimen of fluconazole in critically ill patients receiving continuous hemodiafiltration. Intensive Care Med. 2003;29:1844–8.PubMedCrossRef
18.
Bergner R, Hoffmann M, Riedel K-D, et al. Fluconazole dosing in continuous veno-venous haemofiltration (CVVHD): need for a high daily dose of 800 mg. Nephrol Dial Transplant. 2006;21:1019–23.PubMedCrossRef
19.
Pai MP, Turpin RS, Garey KW. Association of fluconazole area under the concentration-time curve/MIC and dose/MIC ratios with mortality in nonneutropenic patients with candidemia. Antimicrob Agents Chemother. 2007;51:35–9.PubMedCrossRef
20.
Baddley JW, Patel M, Bhavnani SM, et al. Association of fluconazole pharmacodynamics with nmortality in patients with candidemia. Antimicrob Agents Chemother. 2008;52:3022–8.PubMedCrossRef
21.
• Gallagher JC. Clinical application of antifungal pharmacodynamics. Curr Fungal Infect Rep. 2010;3:69–76. This recent review article provides a brief yet excellent summary of the pharmacodynamics of antifungal agents. CrossRef
22.
Clancy CJ, Yu VL, Morris AJ, et al. Fluconazole MIC and the fluconazole dose/MIC ratio correlate with therapeutic response among patients with candidemia. Antimicrob Agents Chemother. 2005;49:3171–7.PubMedCrossRef
23.
Barriere SL. Pharmacology and pharmacokinetics of traditional systemic antifungal agents. Pharmacother. 1990;10:134S–40S.
24.
•• Hafner V, Czock D, Burhenne J, et al. Pharmacokinetics of sulfobutylether-beta-cyclodextrin and voriconazole in patients with end-stage renal failure during treatment with two hemodialysis systems and hemodiafiltration. Antimicrob Agents Chemother. 2010;54:2596–602. This study examined both voriconazole and the cyclodextrin excipient in patients undergoing several types of intermittent hemodialysis. The article provides the first detailed pharmacokinetic analysis of the pharmacokinetics of sulfobutylether-beta-cyclodextrin during RRT. PubMedCrossRef
25.
Fuhrmann V, Schenk P, Jaeger W, et al. Pharmacokinetics of voriconazole during continuous venovenous haemodiafiltration. J Antimicrob Chemother. 2007;60:1085–90.PubMedCrossRef
26.
Quintard H, Papy E, Massias L, et al. The pharmacokinetic profile of voriconazole during continuous high-volume venovenous hemodiafiltration in a critically ill patient. Ther Drug Monit. 2008;30:117–9.PubMedCrossRef
27.
Burkhardt O, Thon S, Burhenne J, et al. Sulfobutylether-β-cyclodextrin accumulation in critically ill patients with acute kidney injury treated with intravenous voriconazole under extended daily dialysis [letter]. Int J Antimicrob Agents. 2010;36:93–4.PubMedCrossRef
28.
••Luke DR, Tomaszewski K, Damle B, et al. Review of the basic and clinical pharmacology of sulfobutylether-β-cyclodextrin (SBECD). J Pharm Sci. 2010;99:3291–301. This article provides a very comprehensive review of all known data, both animal and human, related to the pharmacokinetics and toxicity of SBECD. The authors make a strong argument for lack of significant toxicity concerns with the use of voriconazole injection in renally impaired patients but acknowledge that the relative lack of detailed data needs to be addressed. PubMedCrossRef
29.
30.
Abel S, Allan R, Gandelman K, et al. Pharmacokinetics, safety and tolerance of voriconazole in renally impaired subjects: Two prospective, multicentre, open-label, parallel-group volunteer studies. Clin Drug Investig. 2008;28:409–20.PubMedCrossRef
31.
von Mach MA, Burhenne J, Weilemann LS. Accumulation of the solvent vehicle sulfobutylether-beta-cyclodextrin sodium in critically ill patients treated with intravenous voriconazole under renal replacement. BMC Clin Pharmacol. 2006;6:6–7.CrossRef
32.
Sporanox (itraconzole) Oral Solution product information. Ortho-McNeil-Janssen Pharmaceuticals Inc. Raritan, New Jersey, USA: November 2009.
33.
Mohr JF, Finkel KW, Rex JH, et al. Pharmacokinetics of intravenous itraconazole in stable hemodialysis patients. Antimicrob Agents Chemother. 2004;48:3151–3.PubMedCrossRef
34.
Patel JH, Churchwell MD, Seroogy JD, et al. Telavancin and hydroxypropyl-beta-cyclodextrin clearance during continuous renal replacement therapy: an in vitro study. Int J Artif Organs. 2009;32:745–51.PubMed
35.
Courtney R, Samsone A, Smith W, et al. Posaconazole pharmacokinetics, safety and tolerability in subjects with varying degrees of chronic renal disease. J Clin Pharmacol. 2005;45:185–92.PubMedCrossRef
36.
Dowell JA, Stogniew M, Krause D, et al. Anidulafungin does not require dosage adjustment in subjects with varying degrees of hepatic or renal impairment. J Clin Pharmacol. 2007;47:461–70.PubMedCrossRef
37.
• Burkhardt O, Kaever V, Burhenne H, et al. Extended daily dialysis does not affect the pharmacokinetics of anidulafungin [letter]. Int J Antimicrob Agents. 2009;34:282–3. This short report provides among the only available data regarding the pharmacokinetics of anidulafungin during extended-duration RRT. PubMedCrossRef
38.
Hirata K, Aoyama T, Matsumoto Y, et al. Pharmacokinetics of antifungal agent micafungin in critically ill patients receiving continuous hemodialysis filtration. Yakugaku Zasshi - J Pharm Soc Jpn. 2007;127:897–901.CrossRef
39.
Gallis HA, Drew RH, Pickard WW. Amphotericin B: 30 years of clinical experience. Rev Infect Dis. 1990;12:308–24.PubMedCrossRef
40.
Bellmann R, Egger P, Wiedermann CJ, et al. Differences in pharmacokinetics of amphotericin B lipid formulations despite clinical equivalence [letter]. Clin Infect Dis. 2003;36:1500–1.PubMedCrossRef
41.
Vermes A, Guchelaar HJ, Dankert J. Flucytosine: a review of its pharmacology, clinical indications, pharmacokineitcs, toxicity and drug interactions. J Antimicrob Chemother. 2000;46:171–9.PubMedCrossRef
42.
Smith J, Andes D. Therapeutic drug monitoring of antifungals: pharmacokinetic and pharmacodynamic considerations. Ther Drug Monit. 2008;30:167–72.PubMedCrossRef
43.
• Roberts JA, Udy AA, O’Donoghue, et al. Clearance of intravenous 5-fluorocytosine during continuous venovenous haemodiafiltration in a patient with hepatosplenic candidiasis [letter]. Int J Antimicrob Agents. 2009;34:383–4. This brief report provides the only available data regarding the pharmacokinetics of 5-FC in patients undergoing CRRT and provides the basis for the dosage recommendations in the current review article. PubMedCrossRef
Metadata
Title
Antifungal Dosing in Dialysis and Continuous Renal Replacement Therapy
Author
Douglas N. Fish
Publication date
01-06-2011
Publisher
Current Science Inc.
Published in
Current Fungal Infection Reports / Issue 2/2011
Print ISSN: 1936-3761
Electronic ISSN: 1936-377X
DOI
https://doi.org/10.1007/s12281-011-0048-8

Other articles of this Issue 2/2011

Current Fungal Infection Reports 2/2011 Go to the issue

Clinical Trial Report

Optimizing Amphotericin B Therapy for Cryptococcal Meningitis

ReviewPaper

Pros and Cons of Extrapolating Animal Data on Antifungal Pharmacodynamics to Humans

ReviewPaper

Update on Antifungal Drug Dosing and Therapeutic Drug Monitoring

ReviewPaper

Antifungal Dosing in Obesity: A Review of the Literature

ReviewPaper

Antifungal Pharmacokinetics and Dosing Considerations in Burn Patients

ReviewPaper

Antifungal Therapy in Pediatric Patients
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits